Analytical Data
-
Gene name
PCDHgA2
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y5H1
-
Expression Region
Gly29~Phe347
-
Molecular Weight
39kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Protocadherin gamma A2 (PCDHgA2) is a member of the protocadherin family, which plays a crucial role in cell adhesion, signaling, and neuronal development. Understanding the structure and function of PCDHgA2 is essential for elucidating its involvement in neural circuit formation and maintenance. Dysregulation of protocadherins has been associated with various neurodevelopmental disorders, making PCDHgA2 a potential target for therapeutic interventions. Recent advances in protein engineering and recombinant DNA technology have enabled the production of PCDHgA2 as a recombinant protein, facilitating detailed studies of its biochemical properties and interactions. Researchers have been investigating its molecular mechanisms, including how it regulates synaptic connectivity and stability in the central nervous system. By generating recombinant PCDHgA2, scientists can perform in vitro assays and structural analyses, which are vital for understanding its role in neuronal networks and for exploring its potential implications in diseases such as autism and schizophrenia. This research not only sheds light on the fundamental biology of cell adhesion molecules but also opens new avenues for the development of targeted therapies aimed at correcting the functional deficits associated with protocadherin-related pathologies.
